Abstract
COVID-19 caused by SARS-CoV-2 is an ongoing global pandemic that causes catastrophic devastation to humankind. COVID-19 virus mainly affects the human respiratory and gastrointestinal systems. Currently, vaccines are available globally and are a game-changer in the fight against COVID- 19. However, it has a long way to go to achieve the war against COVID-19 as it will take some more years to completely vaccinate the people, and there are threats and concerns of COVID-19 due to the high mutagenicity rate of the virus. The current methods of treatment involve the use of antiviral drugs and anti-inflammatory drugs but without much success. To date, there is no established prevention or treatment method for this novel virus. The best preventive strategy to combat this disease is to keep the immune system strong. Evidence showed a correlation between gut dysbiosis, COVID-19, and immunomodulation. Since time immemorial, probiotics have improved general health and immunity to various diseases. Probiotics are beneficial bacteria when administered in the right doses conferring a health benefit to the host. Various scientific evidence has proved the therapeutic and protective effects of probiotics against respiratory and gastrointestinal diseases. This review aims to outline the potential role of probiotics in fighting COVID-19 by highlighting the recent evidence on the association between dysbiosis, COVID-19, and probiotics and outlining the antiviral and anti-inflammatory effects of probiotics. This review highlight the association between gut and lung in the gut-lung axis. Furthermore, this review also provides an insight into the indirect evidence of the potential protective role of probiotics in combating COVID-19 or its associated symptoms.
[1]
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. Available from: https://covid19.who.int/ (Accessed on September 15, 2021)
[2]
Liu C, Zhou Q, Li Y, et al. research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020; 6(3): 315-31.
[http://dx.doi.org/10.1021/acscentsci.0c00272] [PMID: 32226821]
[http://dx.doi.org/10.1021/acscentsci.0c00272] [PMID: 32226821]
[3]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[4]
Bhaskar S, Sinha A, Banach M, et al. Cytokine storm in COVID-19-Iimmunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM consortium position paper. Front Immunol 2020; 11: 1648.
[http://dx.doi.org/10.3389/fimmu.2020.01648] [PMID: 32754159]
[http://dx.doi.org/10.3389/fimmu.2020.01648] [PMID: 32754159]
[5]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 - Final report. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[6]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[7]
Mohtadi N, Ghaysouri A, Shirazi S, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology 2020; 548: 1-5.
[http://dx.doi.org/10.1016/j.virol.2020.05.006] [PMID: 32530808]
[http://dx.doi.org/10.1016/j.virol.2020.05.006] [PMID: 32530808]
[8]
Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol 2020; 92(11): 2516-22.
[http://dx.doi.org/10.1002/jmv.26038] [PMID: 32436994]
[http://dx.doi.org/10.1002/jmv.26038] [PMID: 32436994]
[9]
Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. med Rxiv 2020; 15.
[10]
Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Iran J Clin Infect Dis 2020; 97: 396-403.
[http://dx.doi.org/10.1016/j.ijid.2020.06.099] [PMID: 32623082]
[http://dx.doi.org/10.1016/j.ijid.2020.06.099] [PMID: 32623082]
[11]
Liu Z, Li X, Fan G, et al. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin Microbiol Infect 2021; 27(1): 112-7.
[http://dx.doi.org/10.1016/j.cmi.2020.09.045] [PMID: 33007478]
[http://dx.doi.org/10.1016/j.cmi.2020.09.045] [PMID: 33007478]
[12]
Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 2020; 130(9): 4791-7.
[http://dx.doi.org/10.1172/JCI140200] [PMID: 32525844]
[http://dx.doi.org/10.1172/JCI140200] [PMID: 32525844]
[13]
Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124(4): 837-48.
[http://dx.doi.org/10.1016/j.cell.2006.02.017] [PMID: 16497592]
[http://dx.doi.org/10.1016/j.cell.2006.02.017] [PMID: 16497592]
[14]
Savage DC. Associations of indigenous microorganisms with gastrointestinal mucosal epithelia. Am J Clin Nutr 1970; 23(11): 1495-501.
[http://dx.doi.org/10.1093/ajcn/23.11.1495] [PMID: 5475367]
[http://dx.doi.org/10.1093/ajcn/23.11.1495] [PMID: 5475367]
[15]
Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. FEBS J 2020; 287(5): 833-55.
[http://dx.doi.org/10.1111/febs.15217] [PMID: 31955527]
[http://dx.doi.org/10.1111/febs.15217] [PMID: 31955527]
[16]
Hakim H, Dallas R, Wolf J, et al. Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic leukemia. Clin Infect Dis 2018; 67(4): 541-8.
[http://dx.doi.org/10.1093/cid/ciy153] [PMID: 29518185]
[http://dx.doi.org/10.1093/cid/ciy153] [PMID: 29518185]
[17]
Chen CJ, Wu GH, Kuo RL, Shih SR. Role of the intestinal microbiota in the immunomodulation of influenza virus infection. Inf 2017; 19(12): 570-9.
[http://dx.doi.org/10.1016/j.micinf.2017.09.002] [PMID: 28939355]
[http://dx.doi.org/10.1016/j.micinf.2017.09.002] [PMID: 28939355]
[18]
Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26(7): 1017-32.
[http://dx.doi.org/10.1038/s41591-020-0968-3] [PMID: 32651579]
[http://dx.doi.org/10.1038/s41591-020-0968-3] [PMID: 32651579]
[19]
Xu K, Cai H, Shen Y, et al. Management of coronavirus disease-19 (COVID-19): The Zhejiang experience. J Zhejiang Univ 2020.
[20]
Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with Coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis 2020; 71(10): 2669-78.
[http://dx.doi.org/10.1093/cid/ciaa709] [PMID: 32497191]
[http://dx.doi.org/10.1093/cid/ciaa709] [PMID: 32497191]
[21]
Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020; 159(3): 944-955.e8.
[http://dx.doi.org/10.1053/j.gastro.2020.05.048] [PMID: 32442562]
[http://dx.doi.org/10.1053/j.gastro.2020.05.048] [PMID: 32442562]
[22]
Yu L, Tong Y, Shen G, et al. Immunodepletion with hypoxemia: A potential high risk subtype of coronavirus disease 2019. medRxiv 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.03.03.20030650v1
[23]
Han MK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases and the heart. Circulation 2007; 116(25): 2992-3005.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.685206] [PMID: 18086941]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.685206] [PMID: 18086941]
[24]
Dhar D, Mohanty A. Gut microbiota and COVID-19- possible link and implications. Virus Res 2020; 285: 198018.
[http://dx.doi.org/10.1016/j.virusres.2020.198018] [PMID: 32430279]
[http://dx.doi.org/10.1016/j.virusres.2020.198018] [PMID: 32430279]
[25]
Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol 2020; 5(7): 644-5.
[http://dx.doi.org/10.1016/S2468-1253(20)30122-9] [PMID: 32339473]
[http://dx.doi.org/10.1016/S2468-1253(20)30122-9] [PMID: 32339473]
[26]
Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15(1): 55-63.
[http://dx.doi.org/10.1038/nrmicro.2016.142] [PMID: 27694885]
[http://dx.doi.org/10.1038/nrmicro.2016.142] [PMID: 27694885]
[27]
Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. Mucosal Immunol 2019; 12(4): 843-50.
[http://dx.doi.org/10.1038/s41385-019-0160-6] [PMID: 30976087]
[http://dx.doi.org/10.1038/s41385-019-0160-6] [PMID: 30976087]
[28]
Zhang D, Li S, Wang N, Tan H-Y, Zhang Z, Feng Y. the cross-talk between gut microbiota and lungs in common lung diseases. Front Microbiol 2020; 11: 301.
[http://dx.doi.org/10.3389/fmicb.2020.00301] [PMID: 32158441]
[http://dx.doi.org/10.3389/fmicb.2020.00301] [PMID: 32158441]
[29]
Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Re Microbiology 2017; 15(1): 55-63.
[http://dx.doi.org/10.1038/nrmicro.2016.142] [PMID: 27694885]
[http://dx.doi.org/10.1038/nrmicro.2016.142] [PMID: 27694885]
[30]
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10(2): 102-8.
[http://dx.doi.org/10.1016/j.jpha.2020.03.001] [PMID: 32282863]
[http://dx.doi.org/10.1016/j.jpha.2020.03.001] [PMID: 32282863]
[31]
Jin X, Lian J-S, Hu J-H, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020; 69(6): 1002-9.
[http://dx.doi.org/10.1136/gutjnl-2020-320926] [PMID: 32213556]
[http://dx.doi.org/10.1136/gutjnl-2020-320926] [PMID: 32213556]
[32]
Fan J, Li X, Gao Y, et al. The lung tissue microbiota features of 20 deceased patients with COVID-19. J Infect 2020; 81(3): e64-7.
[http://dx.doi.org/10.1016/j.jinf.2020.06.047] [PMID: 32579991]
[http://dx.doi.org/10.1016/j.jinf.2020.06.047] [PMID: 32579991]
[33]
Bondy GS, Pestka JJ. Immunomodulation by fungal toxins. J Toxicol Environ Health Part B Crit Rev 2000; 3: 109-43.
[34]
Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 2009; 462(7272): 449-60.
[http://dx.doi.org/10.1038/nature08604] [PMID: 19940915]
[http://dx.doi.org/10.1038/nature08604] [PMID: 19940915]
[35]
Khaneghah AM, Abhari K, Eş I, et al. Interactions between probiotics and pathogenic microorganisms in hosts and foods: A review. Trends Food Sci Technol 2020; 95: 205-18.
[http://dx.doi.org/10.1016/j.tifs.2019.11.022]
[http://dx.doi.org/10.1016/j.tifs.2019.11.022]
[36]
Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11(8): 506-14.
[http://dx.doi.org/10.1038/nrgastro.2014.66] [PMID: 24912386]
[http://dx.doi.org/10.1038/nrgastro.2014.66] [PMID: 24912386]
[37]
Stavropoulou E, Bezirtzoglou E. Probiotics in medicine: A long debate. Front Immunol 2020; 11: 2192.
[http://dx.doi.org/10.3389/fimmu.2020.02192] [PMID: 33072084]
[http://dx.doi.org/10.3389/fimmu.2020.02192] [PMID: 33072084]
[38]
Maldonado GC, Cazorla SI, Lemme DJM, Vélez E, Perdigón G. Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab 2019; 74(2): 115-24.
[http://dx.doi.org/10.1159/000496426] [PMID: 30673668]
[http://dx.doi.org/10.1159/000496426] [PMID: 30673668]
[39]
Yan F, Polk DB. Probiotics and immune health. Curr Opin Gastroenterol 2011; 27(6): 496-501.
[http://dx.doi.org/10.1097/MOG.0b013e32834baa4d] [PMID: 21897224]
[http://dx.doi.org/10.1097/MOG.0b013e32834baa4d] [PMID: 21897224]
[40]
Chai W, Burwinkel M, Wang Z, et al. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol 2013; 158(4): 799-807.
[http://dx.doi.org/10.1007/s00705-012-1543-0] [PMID: 23188495]
[http://dx.doi.org/10.1007/s00705-012-1543-0] [PMID: 23188495]
[41]
Starosila D, Rybalko S, Varbanetz L, Ivanskaya N, Sorokulova I. Anti-influenza activity of a Bacillus subtilis probiotic strain. Antimicrob Agents Chemother 2017; 61(7): e00539-17.
[http://dx.doi.org/10.1128/AAC.00539-17] [PMID: 28416546]
[http://dx.doi.org/10.1128/AAC.00539-17] [PMID: 28416546]
[42]
Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep 2019; 9(1): 4812.
[http://dx.doi.org/10.1038/s41598-019-39602-7] [PMID: 30886158]
[http://dx.doi.org/10.1038/s41598-019-39602-7] [PMID: 30886158]
[43]
Luoto R, Ruuskanen O, Waris M, Kalliomäki M, Salminen S, Isolauri E. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial. J Allergy Clin Immunol 2014; 133(2): 405-13.
[http://dx.doi.org/10.1016/j.jaci.2013.08.020] [PMID: 24131826]
[http://dx.doi.org/10.1016/j.jaci.2013.08.020] [PMID: 24131826]
[44]
de Vrese M, Winkler P, Rautenberg P, et al. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: A double blind, randomized, controlled trial. Clin Nutr 2005; 24(4): 481-91.
[http://dx.doi.org/10.1016/j.clnu.2005.02.006] [PMID: 16054520]
[http://dx.doi.org/10.1016/j.clnu.2005.02.006] [PMID: 16054520]
[45]
Yu HS, Lee NK, Choi AJ, Choe JS, Bae CH, Paik HD. Anti-inflammatory potential of probiotic strain weissella cibaria JW15 isolated from kimchi through regulation of NF-κB and MAPKs pathways in LPS-induced RAW 264.7 cells. J Microbiol Biotechnol 2019; 29(7): 1022-32.
[http://dx.doi.org/10.4014/jmb.1903.03014] [PMID: 31216608]
[http://dx.doi.org/10.4014/jmb.1903.03014] [PMID: 31216608]
[46]
Kim SO, Sheikh HI, Ha SD, Martins A, Reid G. G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages. Cell Microbiol 2006; 8(12): 1958-71.
[http://dx.doi.org/10.1111/j.1462-5822.2006.00763.x] [PMID: 16889627]
[http://dx.doi.org/10.1111/j.1462-5822.2006.00763.x] [PMID: 16889627]
[47]
Angurana SK, Bansal A, Singhi S, et al. Evaluation of effect of probiotics on cytokine levels in critically Ill children with severe sepsis: A double-blind, placebo-controlled trial. Crit Care Med 2018; 46(10): 1656-64.
[http://dx.doi.org/10.1097/CCM.0000000000003279] [PMID: 29957709]
[http://dx.doi.org/10.1097/CCM.0000000000003279] [PMID: 29957709]
[48]
Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606.
[http://dx.doi.org/10.1136/bmj.m606] [PMID: 32075786]
[http://dx.doi.org/10.1136/bmj.m606] [PMID: 32075786]
[49]
d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the management of SARS-CoV-2 infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med (Lausanne) 2020; 7: 389.
[http://dx.doi.org/10.3389/fmed.2020.00389] [PMID: 32733907]
[http://dx.doi.org/10.3389/fmed.2020.00389] [PMID: 32733907]
